BerGenBio Therapy Reins in Lung and Liver Tissue Scarring, Research Shows

BerGenBio’s bemcentinib (BGB324) stops the progression of aggressive tissue scarring in the lungs and liver, preclinical-trial research shows. Researchers published the findings in the American Journal of Respiratory and Critical Care Medicine. The article is titled “Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.” The results were also presented…